$Ovid Therapeutics(OVID)$ 首付款拿了2个亿
entered into a Royalty, License and Termination Agreement (the “New Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”), relating to the prior License and Collaboration Agreement that the Company entered into with Takeda in January 2017 (the “Prior Agreement”).
At closing, the Company will receive an upfront payment of $196.0 million and is eligible to receive up to an additional $660.0 million in development, regulatory and sales milestones. In addition, if soticlestat achieves regulatory approval, we will receive tiered royalties on net sales of soticlestat at percentages ranging from the low double-digits up to 20 percent, subject to standard reductions in certain circumstances. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.